Austin Lieberman's avatar
$484.4m follower assets
$NARI update. See previous updates in my feed.

Disclosure, I am long.

TLDR: Inari's FLASH registry data is showing low adverse event rates, low mortality rates, requirement of less hospital resources, and a median of 0 days in the ICU post procedure.

The data is showing what management has claimed. Still an uphill battle to convince more surgeons to use their devices vs conventional treatments.

I'm long this one, too. VTE is a huge market and if this continues to lower readmits and hospital costs that hospitals would otherwise have to eat then I think it could become standard care. I'm really curious to see how Delta variant impacts to space impacted procedure vols last quarter.
View 1 more comment
Austin Lieberman's avatar
$484.4m follower assets
$NARI Announces Randomized Controlled Trial
Investor Takeaway: this is another step towards Inari's goal of proving their devices result in better outcomes than catheter-directed thrombolysis which requires the use of thrombolytic drugs.

If the data proves out Inari's thesis, it could potentially increase the amount of pulmonary embolism "PE" patients treated which could create better outcomes for patients and significant growth opportunities for Inari.

From the press release:

“Historically, due to the major bleeding associated with lytic therapy, physicians needed to carefully weigh a patient’s risk of death against the risk of intervention, reserving advanced treatment for only the sickest of PE patients,” said Global Co-Principal Investigator, Dr. Carin Gonsalves, Professor of Radiology and Co-Director of the Division of Interventional Radiology at Thomas Jefferson University in Philadelphia, PA.
“By offering patients immediate symptom relief upon removal of significant clot burden without the risks of lytics, the potential for bloodless thrombectomy with the FlowTriever System has fundamentally altered the PE treatment landscape, challenging physicians to rethink risk stratification and the goals of intervention.”

“PEERLESS is the first-ever RCT to compare mechanical thrombectomy to CDT for the treatment of PE and aims to provide definitive data on interventional treatment options for these patients,” added Global Co-Principal Investigator, Dr. Wissam Jaber, PERT Director, and Director of the Cardiac Cath Lab at Emory University Hospital in Atlanta, GA. “The primary outcome for the trial is a hierarchical composite of outcomes including mortality, major bleeding events, clinical deterioration, and length of stay in the intensive care unit. These are highly relevant endpoints for patients and for the hospital systems that care for them.”
“With active engagement on over 30 investigator-initiated studies, and 1,000 patients currently enrolled in our three ongoing VTE registries – CLOUT, FLASH, and FLAME – our clinical pipeline is as robust as ever,” said Bill Hoffman, Inari’s Chief Executive Officer. “PEERLESS opens a new chapter in our clinical story, answering the calls of physicians around the world for randomized control data to inform guidelines and redefine VTE treatment pathways around the world.”

Koyfin Data:

post media
Austin Lieberman's avatar
$484.4m follower assets
Austin Lieberman's avatar
$484.4m follower assets
ztinvesting's avatar
$109.6m follower assets
Healthcare/Medtech Stocks I am Excited About
The healthcare industry is one that is clearly outdated, and from insurance to technology, it is in massive need of disruption. Some companies I am excited about:

$TDOC - telehealth and chronic condition monitoring services

$NNOX - advanced, cheaper, more effective x-ray machines

$LGVW - portable, handheld ultrasound device

$TMDX - machines with the capability to transport live organs

$CLOV - innovative, AI-backed insurance offering for seniors

$ARKG - Ark ETF covering gene-editing, CRISPR, and other themes

Two that I have been watching, but do not own shares of:


What are your thoughts on these companies, and what companies am I missing? I plan to post a longer thread either here or on Twitter sometime soon about why I believe these companies in particular are so disruptive.
Great plays, all with tremendous market position as well. I would play $CRSP outright as I want more exposure than just through $ARKG. $PACB poised for upside as well imo. Thanks for posting!
View 3 more comments
Next
Commonstock is a social network that amplifies the knowledge of the best investors, verified by actual track records for signal over noise. Community members can link their existing brokerage accounts and share their real time portfolio, performance and trades (by percent only, dollar amounts never shared). Commonstock is not a brokerage, but a social layer on top of existing brokerages helping to create more engaged and informed investors.